文献速递头颈与中枢神经肿瘤

靶向肿瘤微管的药物筛选鉴定PKC调节剂为胶质母细胞瘤多效抑制剂

Screening for Tumor Microtube-Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression.
PubMed 文献 · Cancer Discov · 2026-01-01

该研究建立了体外/体内联合抗肿瘤微管药物筛选流程,并整合机器学习分析,发现两种PKC调节剂可抑制肿瘤微管形成及肿瘤细胞网络通讯。PKC激活剂TPPB联合放疗经活体双光子显微镜及空间多组学验证,显示抗肿瘤微管与抗肿瘤效应,并降低TTYH1表达。

要点

  • 建立抗肿瘤微管药物筛选流程,可鉴定靶向胶质母细胞瘤神经样特性的化合物。
  • 两种PKC调节剂抑制肿瘤微管形成及起搏肿瘤细胞驱动的网络通讯。
  • PKC激活剂TPPB联合放疗显示抗肿瘤微管与抗肿瘤效应,并降低TTYH1表达。

核心结论

  • PKC调节剂可抑制肿瘤微管形成及胶质母细胞瘤细胞网络通讯,支持靶向肿瘤微管作为脑肿瘤治疗策略。

研究设计与样本

  • 研究建立体外/体内联合抗肿瘤微管药物筛选方法,纳入机器学习分析工具,并在胶质母细胞瘤模型中验证。

主要发现

  • 两种PKC调节剂稳健抑制肿瘤微管形成及起搏肿瘤细胞驱动的、肿瘤微管介导的胶质母细胞瘤细胞网络通讯。
  • 肿瘤微管未连接的肿瘤细胞对细胞毒治疗敏感性增加。
  • PKC激活剂TPPB联合放疗后,长期活体双光子显微镜联合空间分辨多组学显示抗肿瘤微管和抗肿瘤效应。
  • TPPB治疗降低TTYH1表达,TTYH1为侵袭性肿瘤微管的关键驱动因子。

临床怎么用

  • 提示PKC调节剂联合放疗可能通过靶向肿瘤微管增强胶质母细胞瘤治疗效果,但尚未进入临床推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Glioblastomas are incurable primary brain tumors that depend on neural-like cellular processes, tumor microtubes (TM), to invade the brain. TMs also interconnect single tumor cells to a communicating multicellular network that resists current therapies. In this study, we developed a combined, comprehensive in vitro/in vivo anti-TM drug screening approach, including machine learning-based analysis tools. Two protein kinase C (PKC) modulators robustly inhibited TM formation and pacemaker tumor cell-driven, TM-mediated glioblastoma cell network communication. As TM-unconnected tumor cells exhibited increased sensitivity to cytotoxic therapy, the PKC activator TPPB was combined with radiotherapy, and long-term intravital two-photon microscopy paired with spatially resolved multiomics revealed anti-TM and antitumor effects. TPPB treatment also decreased the expression of tweety family member 1 (TTYH1), a key driver of invasive TMs. Our study establishes a novel screening pipeline for anti-TM drug development, identifies a TM master regulator pathway, and supports the approach of TM targeting for efficient brain tumor therapies. SIGNIFICANCE: Cancers can hijack neural properties to grow, disseminate, and to resist therapies, but effective drug development pipelines against these features are missing. Here, we establish a compound screening approach that allowed the identification of PKC modulators that target cancer cell-intrinsic neurodevelopmental mechanisms, suggesting a new class of neuroscience-instructed cancer therapeutics.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Azorín DD, Hoffmann DC, Hebach NR, et al. Screening for Tumor Microtube-Targeting Drugs Identifies PKC Modulators as Multipotent Inhibitors of Glioblastoma Progression. Cancer Discov. 2026. PMID: 41065276. doi:10.1158/2159-8290.CD-24-0414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。